Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
Want to see SION full AI Analyst Report?
SION Stock Chart & Stats
$43.54
$0.55(1.26%)
At close: 4:00 PM EST
$43.54
$0.55(1.26%)
Day’s Range― - ―
52-Week Range$10.97 - $46.46
Previous CloseN/A
Volume33.51K
Average Volume (3M)310.85K
Market Cap
$1.68B
Enterprise Value$1.63B
Total Cash (Recent Filing)$235.88M
Total Debt (Recent Filing)$8.68M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
May 18, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding44,998,074
10 Day Avg. Volume362,732
30 Day Avg. Volume310,850
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.10K
Enterprise Value/Ebitda-21.72
Forecast
1Y Price Target
$53.00Price Target Upside21.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Combination Therapy PotentialPositive interaction data showing SION-719 can be combined with standard therapy raise the prospect that adding the compound could produce additional sweat chloride reduction and validate combination strategies.
Early Clinical Safety And PharmacokineticsPhase 1 results indicating intended exposures at low doses with a favorable tolerability profile support dose selection for larger studies and reduce early clinical development risk.
Pipeline Expansion And Development StrategyAdvancing multiple candidates in combination and standalone programs broadens clinical development opportunities and creates several potential value-driving pathways for the portfolio.
Bears Say
Financial And Operating RiskRising personnel-related selling and administrative expenses combined with high cash burn could shorten the cash runway and raise the likelihood of needing additional, potentially dilutive, financing.
Target FeasibilityThe ATP-binding site within the NBD1 region appears difficult to target without disrupting channel activity, which could complicate discovery efforts and limit the effectiveness of NBD1-directed drugs.
Trial Design And Endpoint RiskA small crossover study with limited treatment duration increases reliance on sweat chloride as the primary efficacy measure and may constrain ability to demonstrate clinically meaningful lung function improvements.
Sionna Therapeutics, Inc. News
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $10.96 and its highest was $46.46 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $1.68B.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
Sionna Therapeutics, Inc.’s upcoming earnings report date is May 18, 2026 which is in 18 days.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on Mar 19, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.539 by $0.079.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate is -0.52.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 44,998,074 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.539. Following the earnings report the stock price went up 3.169%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sionna Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$53.00 (21.73% Upside)
$53.00 (21.73% Upside)
Blogger Sentiment
Bullish
SION Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 540.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
394.64%
12-Months-Change
Fundamentals
Return on Equity
-22.87%
Trailing 12-Months
Asset Growth
76.54%
Trailing 12-Months
Company Description
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
SION Stock 12 Month Forecast
Average Price Target
$53.00
▲(21.73% Upside)
Technical Analysis
Stoke Therapeutics
―
Vir Biotechnology
―
Immatics
―
Tango Therapeutics
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
35.92% Insiders
9.94% Mutual Funds
0.04% Other Institutional Investors
48.18% Public Companies and
Individual Investors